Metropolis Healthcare financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹450cr+16.6% on Q1 FY26
Net profit
₹56.9cr+25.7% on Q1 FY26
EBITDA margin
24.7%+1.4 pts on Q1 FY26
EPS
₹2.73−68.6% on Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue450386+16.6%
EBITDA11189.8+23.9%
EBITDA margin24.7%23.3%+1.4 pts
Profit before tax77.761.2+26.9%
Net profit56.945.2+25.7%
EPS₹2.73₹8.70−68.6%

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹450 crNet profit₹56.9 crNet margin12.6%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
11,428————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
19519510911681.9
11.411.43.73.12.5
18.718.714.20.079.1
11,263————
1,7101,6461,3311,2081,148
—+23.6%+10.2%+5.2%—
422401303283288
24.7%24.4%22.8%23.4%25.1%
287267194188199
203191146128143
11.9%11.6%10.9%10.6%12.5%
₹9.72₹9.17₹6.99₹6.16₹6.89
—+31.1%+13.4%−10.5%—
—351263264247
—−51.2−68.6−63.8−52.6
300300194200194
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

METROPOLIS₹551.20

Metropolis Healthcare Ltd.

· Pharma & Health
₹ CrorePeersLALPATHLABVIJAYATHYROCAREMARKSANSPARKHOSPSJLHLRUBICONHCGMcap ₹11,428 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————11,427.9
- Cash, Equiv & ST Investments81.9115.7108.7195.4195.4
+ Minority Interest2.53.13.711.411.4
+ Total Debt79.10.014.218.718.7
Enterprise Value————11,262.6
Revenue1,148.21,207.71,331.21,645.81,710.0
Growth %, YoY—+5.2+10.2+23.6—
EBITDA288.3282.6303.0400.8422.3
Margin %25.1123.4022.7624.3624.69
EBIT199.1188.1194.3267.1287.0
Net Income143.4128.5145.5191.2202.8
Margin %12.4910.6410.9311.6211.86
EPS, Adj (current shares)6.896.166.999.179.72
Growth %, YoY—-10.5+13.4+31.1—
Cash from Operations247.1264.1262.7350.7—
Capital Expenditures-52.6-63.8-68.6-51.2—
Free Cash Flow194.5200.3194.1299.5299.5
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Metropolis Healthcare financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Metropolis Healthcare (NSE: METROPOLIS) had a market capitalisation of ₹11,483 crore at the 29 October 2026 close (₹553.85 a share), a PE ratio of 57.0 on the last four quarters' profit and a price-to-book ratio of 7.59. In FY26 its consolidated net profit was ₹190 crore on revenue of ₹1,646 crore; in Q1 FY27 (April–June 2026) it was ₹56.7 crore, up 25.8% year on year. Its debt-to-equity ratio was 0.01 on 31 March 2026. Promoters held 47.82% of the shares on 30 September 2026.

Share price used
₹553.85 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Metropolis Healthcare at a glance · consolidated

Market cap
₹11,483 Crat ₹553.85 · 29 Oct close
PE ratio (last 4 quarters)
57.060.4 on FY26 profit
Price to book (PB)
7.59book value ₹72.98 a share
ROE (FY26)
13.4%+1.4 pts vs FY25ROCE 15.8%
Debt to equity
0.01net cash ₹184 Cr
Promoter holding
47.82%−1.0 pts vs 30 Jun 202630 September 2026
Net worth
₹1,513 Cr+13.7% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹300 Cr+54.3% vs FY25
EPS (FY26)
₹9.19

Questions

What is the Metropolis Healthcare PE ratio today?

Metropolis Healthcare's PE ratio is 57.0 at the 29 October 2026 close (₹553.85 a share): a market capitalisation of ₹11,483 crore divided by consolidated net profit of ₹202 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹190 crore) it is 60.4.

What is the Metropolis Healthcare PB ratio (price to book value)?

Metropolis Healthcare's price-to-book (PB) ratio is 7.59 at the 29 October 2026 close: a market capitalisation of ₹11,483 crore divided by shareholders' equity (book value) of ₹1,513 crore on 31 March 2026. That is a book value of ₹72.98 per share against a share price of ₹553.85.

What is the Metropolis Healthcare net worth?

Metropolis Healthcare's net worth — shareholders' equity in its consolidated balance sheet — was ₹1,513 crore on 31 March 2026, up 13.7% from ₹1,331 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹11,483 crore at the 29 October 2026 close.

What is the Metropolis Healthcare market cap?

Metropolis Healthcare's market capitalisation was ₹11,483 crore at the 29 October 2026 close: 20.73 crore shares at ₹553.85 each.

Is Metropolis Healthcare debt free?

No. Metropolis Healthcare had borrowings of ₹18.7 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.01. Its cash and current investments were ₹203 crore, so it held net cash of ₹184 crore.

What is the Metropolis Healthcare dividend in 2026 and its record date?

In 2026, Metropolis Healthcare has declared one dividend: ₹1 (interim) with record date 19 May 2026.

What is the Metropolis Healthcare debt to equity ratio?

Metropolis Healthcare's debt-to-equity ratio was 0.01 on 31 March 2026: borrowings of ₹18.7 crore against total equity of ₹1,525 crore. A year earlier, on 31 March 2025, it was 0.01.

What is the Metropolis Healthcare book value per share?

Metropolis Healthcare's book value per share was ₹72.98 on 31 March 2026: shareholders' equity of ₹1,513 crore divided by the 20.73 crore shares in issue. The share price at the 29 October 2026 close was ₹553.85.

What is the Metropolis Healthcare promoter holding?

Promoters held 47.82% of Metropolis Healthcare on 30 September 2026, down 1.04 percentage points from 48.86% the previous quarter and down 1.07 percentage points from 48.89% a year earlier, according to the shareholding pattern filed with NSE.

What is the Metropolis Healthcare ROE and ROCE?

In FY26, Metropolis Healthcare's return on equity (ROE) was 13.4% and its return on capital employed (ROCE) was 15.8%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 12.0% and ROCE 13.5%.

What is the Metropolis Healthcare shareholding pattern?

On 30 September 2026, Metropolis Healthcare's shares were held by promoters 47.82%, foreign portfolio investors (FII/FPI) 11.67%, domestic institutions (DII) 35.49% (including mutual funds at 33.09%) and retail and other non-institutional investors 5.02%. Over the year, FII holding was down 0.85 percentage points from 12.52% and DII holding was up 2.39 percentage points from 33.10%.

How does the Metropolis Healthcare PE ratio compare with its peers?

At the 29 October 2026 closing prices, on FY26 net profit, Metropolis Healthcare's PE ratio is 60.4, the third highest of the four: Dr. Lal Path Labs 63.5, Vijaya Diagnostic Centre 87.1 and Thyrocare Technologies 50.3, a peer average of 67.0. Each is the company's market capitalisation at that price divided by its FY26 net profit.

What is the Metropolis Healthcare EPS?

Metropolis Healthcare's basic earnings per share (EPS) were ₹9.19 in FY26.

What is the Metropolis Healthcare free cash flow?

In FY26, Metropolis Healthcare generated ₹351 crore of cash from operations and spent ₹51.2 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹300 crore. In FY25 it was ₹194 crore.

When are the Metropolis Healthcare next results?

Metropolis Healthcare will announce its Q2 FY27 results (July–September 2026) on Tuesday, 3 November 2026, the date of the board meeting it has notified to the exchanges.

What are the Metropolis Healthcare latest quarterly results?

Metropolis Healthcare's latest results are for Q1 FY27 (April–June 2026), filed on 4 August 2026: consolidated net profit ₹56.7 crore, up 25.8% from ₹45.1 crore in Q1 FY26; revenue from operations ₹450 crore, up 16.6% year on year.

What is the Metropolis Healthcare revenue and profit in FY26?

In FY26 (April 2025–March 2026), Metropolis Healthcare's consolidated net profit was ₹190 crore, up 31.1% from ₹145 crore in FY25, on revenue from operations of ₹1,646 crore (up 23.6%). Over three years, from FY23, net profit was up 33.0%.

Metropolis Healthcare vs Dr. Lal Path Labs: how do they compare?

In FY26, Metropolis Healthcare earned net profit of ₹190 crore on revenue of ₹1,646 crore, against ₹505 crore on ₹2,763 crore for Dr. Lal Path Labs. Metropolis Healthcare's operating margin was 16.2% (Dr. Lal Path Labs 22.5%) and its return on equity 13.4% (Dr. Lal Path Labs 21.6%). At the 29 October 2026 close, Metropolis Healthcare's market capitalisation was ₹11,483 crore against ₹32,040 crore for Dr. Lal Path Labs, and its PE ratio on FY26 profit 60.4 against 63.5.

How does Metropolis Healthcare compare with its peers?

On FY26 consolidated figures, against Dr. Lal Path Labs, Vijaya Diagnostic Centre and Thyrocare Technologies: Metropolis Healthcare's operating margin of 16.2% is the lowest of the four (Dr. Lal Path Labs 22.5%, Vijaya Diagnostic Centre 30.1%, Thyrocare Technologies 24.5%; peer average 25.7%); its return on equity of 13.4% is the lowest of the four (Dr. Lal Path Labs 21.6%, Vijaya Diagnostic Centre 19.7%, Thyrocare Technologies 28.8%; peer average 23.4%); its revenue growth over three years of 12.8% a year is the third highest of the four (Dr. Lal Path Labs 11.1% a year, Vijaya Diagnostic Centre 21.0% a year, Thyrocare Technologies 16.3% a year; peer average 16.1% a year).

Where do these Metropolis Healthcare figures come from?

From Metropolis Healthcare's own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.